Supplementary Figure. Viral RNA Shedding Levels for Individual Subjects With Viral RNA Rebound Among Subjects in the EPIC-HR Trial Who Met the Definitions of Posttreatment Viral RNA Rebound on Day 10 (a) or 14 (B); Those Who Met the Definition of Viral RNA Rebound During the Treatment Period From Day 3 to Day 5* (C, D); Those in the EPIC-SR 2021/Pre-Omicron (E) and 2022/Omicron Enrollment Periods (F), Who Met the Definition of Day 10 or Day 14 Viral RNA Rebound

Advanced Search

Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.

Search our Collections & Repository

Advanced Search
Custom Query

All these words:

For very narrow results

This exact word or phrase:

When looking for a specific result

Any of these words:

Best used for discovery & interchangable words

None of these words:

Recommended to be used in conjunction with other fields

Language:

Dates

Publication Date Range:

to

Document Data

Title:

Document Type:

Library

Collection:

Series:

People

Author:

Clear All

Query Builder

Query box

Clear All

For additional assistance using the Custom Query please check out our Help Page

CDC STACKS serves as an archival repository of CDC-published products including scientific findings, journal articles, guidelines, recommendations, or other public health information authored or co-authored by CDC or funded partners. As a repository, CDC STACKS retains documents in their original published format to ensure public access to scientific information.

i

Supplementary Figure. Viral RNA Shedding Levels for Individual Subjects With Viral RNA Rebound Among Subjects in the EPIC-HR Trial Who Met the Definitions of Posttreatment Viral RNA Rebound on Day 10 (a) or 14 (B); Those Who Met the Definition of Viral RNA Rebound During the Treatment Period From Day 3 to Day 5* (C, D); Those in the EPIC-SR 2021/Pre-Omicron (E) and 2022/Omicron Enrollment Periods (F), Who Met the Definition of Day 10 or Day 14 Viral RNA Rebound

12/22/2023
By Centers for Disease Control and Prevention (U.S.)
Source: MMWR: Morbidity and Mortality Weekly Report 2023; v. 72, no. 51
Series: Weekly Report: Morbidity and Mortality Weekly Report (MMWR)

English

Details Related Documents You May Also Like

Details:

Alternative Title:

Evaluation of SARS-CoV-2 RNA Rebound After Nirmatrelvir/Ritonavir Treatment in Randomized, Double-Blind, Placebo-Controlled Trials — United States and International Sites, 2021–2022: Supplementary Figure. Viral RNA Shedding Levels for Individual Subjects With Viral RNA Rebound Among Subjects in the EPIC-HR Trial Who Met the Definitions of Posttreatment Viral RNA Rebound on Day 10 (a) or 14 (B); Those Who Met the Definition of Viral RNA Rebound During the Treatment Period From Day 3 to Day 5* (C, D); Those in the EPIC-SR 2021/Pre-Omicron (E) and 2022/Omicron Enrollment Periods (F), Who Met the Definition of Day 10 or Day 14 Viral RNA Rebound
Corporate Authors:

Centers for Disease Control and Prevention (U.S.)
Source:

MMWR: Morbidity and Mortality Weekly Report 2023; v. 72, no. 51
Series:

Weekly Report: Morbidity and Mortality Weekly Report (MMWR)
ISSN:

0149-2195 (print);1545-861X (digital);
Document Type:

Journal Article
Place as Subject:

United States
Pages in Document:

1 pdf page
Volume:

72
Issue:

51
Collection(s):

Morbidity and Mortality Weekly Report (MMWR)
Main Document Checksum:

[+]

urn:sha-512:3acfaca33598d65d85b284c876218aae47bc6389aafd0a5626039c9a60b213f99c563c9c36ac6113dce8a285c17f7e354c7c50f37db629544d671ac54aeff402
Download URL:

https://stacks.cdc.gov/view/cdc/136167/cdc_136167_DS1.pdf
File Type:

[PDF-1.13 MB]